AIDS Treatment News logo      

October 22, 2010

Merck Announces Expanded Co-Pay Assistance Program for ISENTRESS® (raltegravir)

Merck: "Merck today announced an enhanced co-pay assistance program for people living with HIV-1 who are taking the Company's first-in-class HIV-1 integrase inhibitor, ISENTRESS® (raltegravir) Tablets. The program provides important savings for privately-insured patients with out-of-pocket costs for ISENTRESS, and is part of Merck’s ongoing commitment to providing access to treatment."